AzTrials
AzTrials

Obstructive Sleep ApneaNCT05266131

The Effect of Sleep Apnea and Hypertension on Gut Microbiome

An observational study of Obstructive Sleep Apnea and Hypertension, run by Peking University First Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Obstructive sleep apnea (OSA) and hypertension are closely associated diseases. Here we characterized the differences in the gut microbiome which is affected by the two diseases, when the two diseases coexist or are present alone. Read more about this study

Who is it for?
Ages 18 years and older
How many people
52 participants
Where
1 siteChina
Study dates
1 Jul 2017to 28 May 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Participants were divided into four groups according to whether they had a confirmed diagnosis of essential HT and OSA (AHI ≥15 beats/h (International Classification of Sleep Disorders (3rd edition) ), as follows. Individuals without OSA and HT belonged to group OSA0HT0; individuals with both OSA and HT were in group OSA1HT1; individuals without OSA but with HT were in group OSA0HT1; and individuals with OSA but without HT were in the group OSA1HT0.

Who may be able to join

  • age 18 years or older
  • outpatients and inpatients who underwent a PSG study for snoring
  • those who volunteered for this study and signed an informed consent form

Who cannot join

  • patients who were treated for OSA (regular CPAP therapy, oral appliances, maxillofacial surgery, etc.) prior to enrolment
  • patients with secondary HT with a clear primary cause
  • those with a history of dyspeptic disease (history of gastrointestinal surgery, peptic ulcer, inflammatory bowel disease, chronic pancreatitis, etc.)
  • those who had organ insufficiency, were receiving immune agents or glucose
  • those who had received antibiotic treatment in the last 2 months or had taken probiotic products (yogurt, milk, cheese, etc.) continuously (daily) for the last 2 months
  • Alcohol or drug dependency

Trial locations and contacts

1 site in 1 country.

China1 site
  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034

Other trials in China

About this study

Official title: Gut Microbiome Characteristics in the Human Cohort With OSA/Hypertension

Obstructive sleep apnea (OSA) and hypertension are closely associated diseases. Here we characterized the differences in the gut microbiome which is affected by the two diseases, when the two diseases coexist or are present alone.

Fifty-two consecutive patients who underwent polysomnography (PSG) were enrolled and divided into four groups: without OSA or hypertension (OSA0HT0), OSA without hypertension (OSA1HT0), hypertension without OSA (OSA0HT1), and with OSA and hypertension (OSA1HT1). Fecal specimens were collected for 16S rRNA sequencing and the characteristics of community richness, diversity, and composition of the gut microbiome and their relationship with disease were analyzed using bioinformatics methods.

Read the detailed description
  1. Participants Participants who underwent overnight polysomnography (PSG) in the sleep laboratory of Peking University First Hospital from July 2017 to November 2017 were included in the study. This study was approved by the ethics committee of the Peking University First Hospital. The study adhered to the Declaration of Helsinki, and patient confidentiality was maintained. All participants signed the informed consent form. The inclusion criteria were as follows: (1) age 18 years or older; (2) outpatients and inpatients who underwent a PSG study for snoring; (3) those who volunteered for this study and signed an informed consent form. Exclusion criteria were: (1) patients who were treated for OSA (regular CPAP therapy, oral appliances, maxillofacial surgery, etc.) prior to enrolment; (2) patients with secondary HT with a clear primary cause; (3) those with a history of dyspeptic disease (history of gastrointestinal surgery, peptic ulcer, inflammatory bowel disease, chronic pancreatitis, etc.); (4) those who had organ insufficiency, were receiving immune agents or glucose; (5) those who had received antibiotic treatment in the last 2 months or had taken probiotic products (yogurt, milk, cheese, etc.) continuously (daily) for the last 2 months. (6) Alcohol or drug dependency.
  2. Questionnaire survey A uniformly designed questionnaire including questions regarding general information, previous history of HT, coronary heart disease, diabetes mellitus, recent history of infection, medication, smoking and drinking history, and dietary habits was used.
  3. Obstructive sleep apnea assessment and HBI calculation Patients underwent regular overnight PSG (Compumedics, E-Series). Standard PSG was conducted according to the American Academy of Sleep Medicine manual (AASM)[11]; that is, six electroencephalography (EEG) channels (C3-M2, C4-M1, F3-M2, F4-M1, O1-M2, O2-M1), two electrooculography channels (E1-M2, E1-M2), chin electromyography (EMG1-EMG2, EMG1-EMG3), electrocardiography, respiration (nasal pressure, airflow), SpO2, abdominal and chest movements, and leg movements were recorded . Sleep stages were divided into three non-REM (N1, N2, N3), REM (R), and wake (W) stages. Respiratory events included obstructive apnoea, central apnea, mixed apnea, and hypopnea. The apnea and hypopnea index (AHI) (sum of the number of apnea and hypopnea events per hour) was calculated. Sleep stage, apnea, and hypopnea events were scored according to the American Academy of Sleep Medicine manual 2.3. The HBI (the hypoxia burden index) was calculated as the integral area under the desaturation curve divided by TST. The area under the desaturation curve was obtained by calculating the integral of the oxygen saturation reduction below 90% and the corresponding time. Higher HBI values are related to a higher hypoxic load (duration and degree). Calculations were performed with MATLAB 2016 for Windows (The Mathworks, Inc., Natick, USA). Specific methods refer to our previous report.
  4. Blood pressure measurement and specimen collection Blood pressure was measured before going to sleep and immediately after waking up. Fecal samples of 1-3 g was collected from the patients in the morning of the following day and immediately frozen in a -80℃ refrigerator by the researcher for later use.
  5. Information collection, entry, and participant grouping. The enrolment number, sex, age, height, weight, Epworth sleep scale (ESS), HT and medication, other major medical and personal histories of all participants in the questionnaire, and the PSG report parameters, mainly AHI, were compiled and entered into an electronic form. Participants were divided into four groups according to whether they had a confirmed diagnosis of essential HT and OSA (AHI ≥15 beats/h (International Classification of Sleep Disorders (3rd edition), as follows. Individuals without OSA and HT belonged to group OSA0HT0; individuals with both OSA and HT were in group OSA1HT1; individuals without OSA but with HT were in group OSA0HT1; and individuals with OSA but without HT were in the group OSA1HT0.
  6. 16S rRNA sequencing analysis of the gut microbiome DNA extraction and sequencing of 16S rRNA coding genes were performed on all fecal samples. This part of the experiment and analysis was conducted at Novogene Bioinformatics Technology Co. Ltd. (Beijing, China) .
  7. Fecal analysis 7.1. Extraction of genome DNA Total genomic DNA from human fecal samples was extracted using cetyltrimethylammonium bromide (CTAB) /sodium dodecyl sulfonate (SDS), according to the manufacturer's instructions. DNA concentration and purity was monitored on 1% agarose gels. 7.2. Amplicon generation 16S rRNA/18S rRNA/ITS genes of distinct regions (16S V4/16S V3/16S V3-V4/16S V4-V5, 18S V4/18S V9, ITS1/ITS2, and Arc V4) were amplified using specific primers (for example 16S V4: 515F-806R, 18S V4: 528F-706R, 18S V9: 1380F-1510R, et. al) with a barcode. All polymerase chain reactions (PCRs) were performed using Phusion® High-Fidelity PCR Master Mix (New England, Biolabs). 7.3. Polymerase chain reaction products mixing and purification Mix same volume of 1X loading buffer (contained SYB green) with PCR products and operate electrophoresis on 2% agarose gel for detection. PCR products was mixed in equidensity ratios. Then, mixture of PCR products was purified with GeneJETTM Gel Extraction Kit (Thermo Scientific). 7.4. Library preparation and sequencing Sequencing libraries were generated using Ion Plus Fragment Library Kit 48 rxns (Thermo Scientific), according to the manufacturer's recommendations. The library quality was assessed on a fluorometer (Qubit 2.0; Thermo Scientific). Finally, the library was sequenced on an Ion S5TM XL platform and 400 bp/600 bp single-end reads were generated.
  8. Bioinformatics, and statistical analysis 8.1. Single-end reads assembly and quality control 8.1.1 Data split Single-end reads were assigned to samples based on their unique barcode and truncated by cutting off the barcode and primer sequence.

8.1.2 Data Filtration Quality filtering on the raw reads were performed under specific filtering conditions to obtain the high-quality clean reads according to the Cutadapt(V1.9.1)quality controlled process.

8.1.3 Chimera removal The reads were compared with the reference database (Gold database), using the UCHIME algorithm to detect chimeric sequences, which were then removed. Then the Effective Tags were finally obtained.

8.2. Operational taxonomic unit clustering and species annotation 8.2.1 Operational taxonomic unit production Sequences analyses were performed by Uparse software (Uparse v7.0.1001). Sequences with ≥97% similarity were assigned to same operational taxonomic units (OTUs). A representative sequence of each OTU was screened for further annotation.

8.2.2 Species annotation For each representative sequence, the Silva Database was used based on RDP classifier (Version 2.2) algorithm to annotate taxonomic information.

8.2.3 Phylogenetic relationship Construction In order to study the phylogenetic relationship among different OTUs, and the difference of the dominant species in different samples (groups), multiple sequence alignments were conducted using the multiple sequence comparison by log- expectation (MUSCLE) software (Version 3.8.31).

8.2.4 Data Normalization OTUs abundance information were normalized using standard sequence numbers corresponding to the sample with the least sequences. Subsequent analysis of alpha diversity and beta diversity were all performed based on this output normalized data. The Chao1, Shannon, and Simpson indices were calculated to estimate alpha diversity and principal coordinate analysis (PCoA) was used to represent beta diversity.

8.3. Alpha Diversity Alpha diversity was applied to analyze the complexity of species diversity in a sample through six indices, including observed species, Chao1, Shannon, Simpson, ACE, Good-coverage. All these indices were calculated with QIIME (Version1.7.0) and displayed using the R software (Version 2.15.3). Chao1 and ACE were selected to identify community richness. Shannon and Simpson indices were used to identify the community diversity.

8.4. Beta Diversity Beta diversity analysis was used to evaluate the differences of samples in species complexity. Beta diversity on both weighted and unweighted unifractions were calculated by QIIME software (Version 1.7.0). PCoA was used to represent Beta diversity.

Medical subject headings
Sleep Apnea, Obstructive, Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05266131
Study groupRoleWhat they receive
OSA0HT0without OSA or hypertension (OSA0HT0)
OSA1HT0OSA without hypertension (OSA1HT0)
OSA0HT1hypertension without OSA (OSA0HT1)
OSA1HT1with OSA and hypertension (OSA1HT1)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 1. Comparisons of the relative community richness of Clostridia of the gut microbiota in OSA0HT0,OSA0HT1,OSA1HT0 and OSA1HT1 group.

    Measured: from July 2017 to November 2017

Secondary outcomes (3)
  1. 2. Comparison of the overall community diversity of the gut microbiome in OSA0HT0,OSA0HT1,OSA1HT0 and OSA1H1 group.

    Measured: from July 2017 to November 2017

  2. 3. Comparison of the overall community richness of the gut microbiome in OSA0HT0,OSA0HT1,OSA1HT0 and OSA1H1 group.

    Measured: from July 2017 to November 2017

  3. 4. Relationship between alpha diversity of the gut microbiome and hypoxia burden of PSG study.

    Measured: from July 2017 to November 2017

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2022
  2. Study start1 Jul 2017
  3. Primary completion30 Nov 2017
  4. Study completion28 May 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
52 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05266131
Sponsor's protocol ID
2018-02
Status last verified
Oct 2024
First submitted
1 Feb 2022
Last updated
22 Oct 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Obstructive Sleep Apnea and Hypertension, run by Peking University First Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

1. Comparisons of the relative community richness of Clostridia of the gut microbiota in OSA0HT0,OSA0HT1,OSA1HT0 and OSA1HT1 group. (time frame: from July 2017 to November 2017). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in